The Science

Osteoarthritis is more
than wear and tear.

Osteoarthritis
is more than wear and tear.

It is an active process, driven by enzymes that break down cartilage.
Stopping those enzymes is the idea behind everything we do.

It is an active process, driven by enzymes that break down cartilage. Stopping those enzymes is the idea behind everything we do.

More than 500 million

people worldwide (WHO)

people worldwide suffer from OA (WHO)

More than 32 million

adults in the U.S. (OA Action Alliance)

Over $1 trillion

global economic burden each year

Current treatments manage symptoms.
None of them are approved to slow the loss of cartilage.

Current treatments manage symptoms.
None of them are approved to slow the loss of cartilage.

Current treatments manage symptoms.
None of them are approved to slow the loss of cartilage.

THE ROOT CAUSE

The root cause: overactive enzymes.

When a joint is injured or inflamed, enzymes called proteases become overactive and start breaking down cartilage. The damage releases signals that cause more inflammation, and the cycle repeats.

A SELF-PERPETUATING CYCLE

01 Injury & inflammation

02 Overactive proteases

03 Cartilage breakdown

04 More inflammatory signals

MEET A2M

A2M: the body’s own enzyme trap.

Alpha-2-macroglobulin (A2M) is a protein your body already makes to keep proteases in check. In a damaged joint, there isn’t enough of it to keep up. Our approach is to put more of it where it’s needed, directly into the joint.

FROM BIOLOGY TO THERAPY

CYT-108: A2M, engineered.

CYT-108 is our investigational therapy: a lab-made version of A2M designed to be 200% more potent than natural A2M. It has completed a Phase 1 clinical study.


200%

Designed to be more potent than natural A2M.

200%

200%

Designed to be more potent than natural A2M.

FROM BIOLOGY TO THERAPY

CYT-108: A2M, engineered.

CYT-108 is our investigational therapy: a lab-made version of A2M designed to be 200% more potent than natural A2M. It has completed a Phase 1 clinical study.


200%

Designed to be more potent than natural A2M.

200%

Designed to be more potent than natural A2M.

PUBLICATIONS

Read the research.

Peer-reviewed studies on A2M, protease biology and the FACT biomarker.

PUBLICATIONS

Read the research.

Peer-reviewed studies on A2M, protease biology and the FACT biomarker.

Investor Presentation
Cytonics: a biotech rebellion

Get updates on CYT-108 and the science behind it.

The company is “testing the waters” of a potential offering which will be conducted under a valid exemption under U.S. Securities laws. No money or other consideration is being solicited, and if sent in response, will not be accepted. Reservations and/or indications of interest involve no obligation or commitment of any kind on any party. This process allows companies to determine whether there may be interest in an eventual offering of its securities. The company is not under any obligation to make an offering. It may choose to make an offering to some, but not all, of the people who indicate an interest in investing. If the company does go ahead with an offering, it will only be able to make sales after it has filed offering documents with the Securities and Exchange Commission (SEC). The information in those offering documents will be more complete than the information the company is providing now, and could differ in important ways. You must read the documents filed with the SEC before investing.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

© 2026 Cytonics Corporation. All rights reserved.